Clinical characteristics in patients with non-alcoholic steatohepatitis in Japan: a case-control study using a 5-year large-scale claims database.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE
    • Publication Information:
      Original Publication: [London] : BMJ Publishing Group Ltd, 2011-
    • Subject Terms:
      Diabetes Mellitus, Type 2* ; Non-alcoholic Fatty Liver Disease*/complications ; Non-alcoholic Fatty Liver Disease*/epidemiology ; Liver Neoplasms*; Aged ; Male ; Humans ; Female ; Middle Aged ; Case-Control Studies ; Japan/epidemiology
    • Abstract:
      Objectives: To examine the clinical characteristics of patients with non-alcoholic steatohepatitis (NASH) and associated comorbidities.
      Design: A case-control study using the national health insurance and the long-term elderly health insurance claims database.
      Setting: Eligible patients diagnosed with NASH (ICD-10 K-75.8, other inflammatory liver disease or K-76.0, other fatty liver) between April 2015 and March 2020 were included.
      Participants: Patients who met the diagnostic definitions for NASH (n=545) were matched with non-NASH controls (n=185 264) and randomly selected according to sex, birth year and residential area.
      Interventions: No interventions were made.
      Primary and Secondary Outcome Measures: ORs were estimated for the relationship between patient background, such as age and sex, body mass index (BMI), NASH-related comorbidities and lifestyle-related diseases.
      Results: In total, 545 patients with NASH (38.3% men) and 185 264 non-NASH controls (43.2% men) were identified, with median ages of 68 (IQR 63.0-75.0) and 65 (IQR 44.0-74.0) years, respectively. BMI was significantly higher in patients with NASH than in controls (25.8 kg/m 2 vs 22.9 kg/m 2 , p<0.001). The proportions of women, patients with hypertension, patients with dyslipidaemia and patients with type 2 diabetes were higher in the NASH group. In addition, NASH was associated with an increased risk of hepatic cirrhosis (OR 28.81 (95% CI 21.79 to 38.08)), followed by liver cancer (OR 18.38 (95% CI 12.56 to 26.89)). There was no significant association between NASH and risk for depression (OR 1.11 (95% CI 0.87 to 1.41)), insomnia (OR 1.12 (95% CI 0.94 to 1.34)) or chronic kidney diseases (OR 0.81 (95% CI 0.58 to 1.12)).
      Conclusions: In the daily medical care of patients, it is necessary to consider sex and age differences and to pay close attention to the risk of liver cancer, as well as other lifestyle-related comorbidities associated with NASH.
      Competing Interests: Competing interests: None declared.
      (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
    • References:
      Hepatology. 2016 Jul;64(1):73-84. (PMID: 26707365)
      J Hepatol. 2017 Oct;67(4):862-873. (PMID: 28642059)
      Osteoporos Int. 2019 May;30(5):975-983. (PMID: 30648192)
      Saudi J Gastroenterol. 2017 Nov-Dec;23(6):311-317. (PMID: 29205182)
      J Gastroenterol. 2011 Jan;46 Suppl 1:63-9. (PMID: 20844903)
      Eur J Clin Invest. 2014 Dec;44(12):1143-9. (PMID: 25293867)
      Dig Dis Sci. 2017 Dec;62(12):3605-3613. (PMID: 29063416)
      J Gastroenterol Hepatol. 2009 Feb;24(2):248-54. (PMID: 19032450)
      J Gastroenterol Hepatol. 2018 Jan;33(1):70-85. (PMID: 28670712)
      J Gastroenterol. 2012 May;47(5):586-95. (PMID: 22328022)
      Clin Gastroenterol Hepatol. 2015 Apr;13(4):643-54.e1-9; quiz e39-40. (PMID: 24768810)
      Ann Intern Med. 2005 Nov 15;143(10):722-8. (PMID: 16287793)
      J Gastroenterol. 2021 Nov;56(11):1022-1032. (PMID: 34601620)
      Intern Med. 2015;54(24):3099-104. (PMID: 26666594)
      Nat Rev Gastroenterol Hepatol. 2016 Apr;13(4):196-205. (PMID: 26907882)
      J Gastroenterol. 2021 Mar;56(3):274-284. (PMID: 33496858)
      Gastroenterology. 2011 Jan;140(1):124-31. (PMID: 20858492)
      Dig Liver Dis. 2012 Dec;44(12):1032-6. (PMID: 22963909)
      J Hepatol. 2016 Jun;64(6):1388-402. (PMID: 27062661)
      Digestion. 2012;86(3):228-37. (PMID: 22964626)
      Gut Liver. 2020 Sep 15;14(5):537-545. (PMID: 31887811)
      Hepatology. 2010 Jun;51(6):1972-8. (PMID: 20209604)
      Hepatology. 2018 Jan;67(1):328-357. (PMID: 28714183)
      Gastroenterology. 2018 Aug;155(2):443-457.e17. (PMID: 29733831)
      J Gastroenterol. 2016 Jun;51(6):586-96. (PMID: 26456168)
      J Hepatol. 2018 Oct;69(4):896-904. (PMID: 29886156)
      Eur J Clin Invest. 2019 Sep;49(9):e13158. (PMID: 31338830)
      World J Gastroenterol. 2016 Apr 28;22(16):4079-90. (PMID: 27122660)
      Dig Dis Sci. 2014 Aug;59(8):1939-45. (PMID: 24718860)
      Hepatology. 2010 Jan;51(1):121-9. (PMID: 19827166)
      J Gastroenterol. 2021 Nov;56(11):951-963. (PMID: 34533632)
      Gastroenterology. 2020 May;158(7):1851-1864. (PMID: 32061595)
      J Gastroenterol Hepatol. 2018 May;33(5):1053-1058. (PMID: 29131401)
    • Contributed Indexing:
      Keywords: Case-Control Studies; Hepatobiliary disease; PUBLIC HEALTH
    • Publication Date:
      Date Created: 20230822 Date Completed: 20230824 Latest Revision: 20230825
    • Publication Date:
      20230825
    • Accession Number:
      PMC10445376
    • Accession Number:
      10.1136/bmjopen-2023-074851
    • Accession Number:
      37607790